共 118 条
[1]
Bendstrup E(2019)Nintedanib in idiopathic pulmonary fibrosis: practical management recommendations for potential adverse events Respiration 97 173-184
[2]
Wuyts W(2021)The safety of nintedanib for the treatment of interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials PLoS ONE 16 e0251636-68
[3]
Alfaro T(2022)Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial Respir Res 23 85-2528
[4]
Chaudhuri N(2019)Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON Lancet Respir Med 7 60-106
[5]
Cornelissen R(2019)Nintedanib for systemic sclerosis-associated interstitial lung disease N Engl J Med 380 2518-2082
[6]
Kreuter M(2021)Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities Respir Res 22 125-1484
[7]
Melgaard Nielsen K(2021)Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial Lancet Respir Med 9 96-undefined
[8]
Münster AMB(2014)Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis N Engl J Med 370 2071-undefined
[9]
Myllärniemi M(2020)Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial Ann Rheum Dis 79 1478-undefined
[10]
Ravaglia C(undefined)undefined undefined undefined undefined-undefined